News
See you at the ID Week 2026 in Washington DC, US
21-24 Oct, 2026
ARIVA Med at the ESCMID Global, Munich, Germany
The ARIVA Med team presented a posters on the novel siderophore-cephalosporin AR-2126
17-21 April 2026
ARIVA Med at the AMR Conference in Basel, Switzerland
The ARIVA Med team presented a posters on the potent
in vitro and
in vivo activity of the novel siderophore cephalosporin AR-2126 against carbapenem-resistant
P. aeruginosa and
A. baumannii
3-4 March 2026
ARIVA Med at the Bio-Europe, Vienna, Austria
We very much enjoyed networking at the Bio-Europe!
Many thanks to the organizers!
2-3 November 2025
ARIVA Med to receive significant grant funding by the Vienna Business Agency, Austria
The Healthcare grant will fund the development of the novel antibiotic Epimutilin AR-7732.
AR-7732 addresses the global health crisis due to antimicrobial resistance (AMR) by its potent antibacterial activity against a variety of resistant bacterial pathogens including multi-drug resistant
Mycobacterium tuberculosis.
May 2025
ARIVA Med at the ESCMID Global 2025 in Vienna, Austria
The ARIVA Med team presented three posters (two selected for eFlash presentation) at the ESCMID Global
11-15 April 2025
Neuer Text
Neuer Text
AMR Conference in Basel, Switzerland, February 2025
The ARIVA Med team attended the AMR conference and pre-conference workshops and enjoyed networking with organizers and attendees
February 2025
ARIVA Med at ESCMID-ASM 2024
INCATE to support ARIVA Med
The INCATE Selection Committee selected the Epimutilins program of ARIVA Med for STAGE I funding.
August 2024